Company Overview - Hims & Hers Health, Inc. is a telehealth company that provides prescription medications, over-the-counter medications, and personal care products [3]. Recent Developments - On June 23, 2025, Novo Nordisk A/S announced the termination of its collaboration with Hims & Hers due to concerns regarding illegal mass compounding and deceptive marketing practices [3]. - Following this announcement, Hims & Hers' stock price experienced a significant decline of over 34% [3]. Legal Investigation - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Hims & Hers, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1].

Market Reaction - Hims & Hers Health shares experienced a significant drop of nearly 35% [1] Partnership Termination - Novo Nordisk is withdrawing from its partnership with Hims & Hers Health [1] Reason for Termination - Novo Nordisk cited "illegal" and "deceptive" practices as the reason for ending the partnership [1]

SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- On June 23, 2025 investors in Hims & Hers Health, Inc. (NYSE: HIMS) saw the price of their shares crash over 30% after Novo Nordisk announced that it terminated its collaboration with the telehealth company due to concerns about Hims & Hers’ sales and “deceptive” marketing of the weight loss drug Wegovy®. This news has prompted national shareholders rights firm Hagens Berman to open an investigation into possible violations of the securities laws. The firm ur ...

Core Viewpoint - Hims & Hers Health has experienced significant growth but faced a major setback due to the termination of its partnership with Novo Nordisk, impacting its stock performance [1][2][3] Company Overview - Hims & Hers Health has established a direct-to-consumer health platform focusing on hair loss, mental health, and weight loss, achieving strong revenue growth and stock returns [1] - The company has seen its stock price increase over 150% on two occasions in early 2025, but it recently dropped over 30% following the partnership news [1][2] Financial Performance - Hims & Hers Health is projected to grow earnings at 36.5% annually over the next three to five years, with sales expected to rise by 58.5% this year and 22.6% next year [5] - Current Zacks Consensus Estimates indicate revenues of $2.34 billion for the current year and $2.87 billion for the next year, reflecting year-over-year growth of 58.48% and 22.63% respectively [7] - The company trades at a premium valuation of 41x next year's earnings, which is considered reasonable given its growth forecasts [5] Market Landscape - The GLP-1 weight loss treatment market is projected to exceed $150 billion by 2035, indicating substantial long-term growth potential despite the recent partnership loss [10] - Novo Nordisk and Eli Lilly, major players in the GLP-1 market, have faced challenges, with Novo Nordisk's shares down over 50% from their 2024 highs [9] Strategic Considerations - The termination of the partnership with Novo Nordisk raises concerns, but Hims & Hers Health remains a fast-growing company in a compelling industry [3][10] - Investors may consider applying a three-day rule to mitigate risks associated with the recent volatility before making investment decisions [11]

Novo Nordisk A/S (NYSE:NVO) stock is down 5.3% to trade at $69.90 at last check, after the drugmaker's obesity drug CagriSema showed no clear advantage over Eli Lilly's (LLY) Zepbound. The company also noted it ended its partnership with Hims and Hers Health (NYSE:HIMS), which granted the latter direct access to its weight loss drug Wegovy via NovoCare Pharmacy.NVO is on track for its sixth-straight daily loss and pacing for its worst day since April 17. The shares are also now testing a familiar floor at t ...

BOSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. Investors who have lost money in their Hims & Hers Health, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/hims. What is this all about? Shares of Hims & Hers Health fell over 25% on June 23 after Novo Nordisk announced it was terminating its partnership ...

Core Insights - Novo Nordisk is terminating its collaboration with Hims & Hers due to concerns over the telehealth company's promotion of cheaper knock-offs of the weight loss drug Wegovy, leading to a 20% drop in Hims & Hers shares in premarket trading [1][4] Group 1: Company Actions - Novo Nordisk had previously partnered with telehealth companies, including Hims & Hers, to expand access to Wegovy after the drug was no longer in short supply in the U.S. [2] - The company accused Hims & Hers of failing to comply with legal restrictions on the mass sale of compounded drugs, which are only allowed under specific circumstances [4] Group 2: Market Impact - The termination of the partnership has resulted in a significant decline in Hims & Hers stock, reflecting investor concerns about the company's future prospects following the news [1]

Core Insights - Hims & Hers Health, Inc. (NYSE: HIMS) has achieved a stock return of 89.5% since the last coverage, significantly outperforming the S&P 500, which declined by 0.85% [1] Leadership & Management Analysis - The company demonstrates a proven track record in scaling businesses, with smart capital allocation and insider ownership [1] - Consistent revenue growth and credible guidance are key attributes of the company's management [1] Market Disruption & Competitive Positioning - Hims & Hers possesses a strong technology moat and first-mover advantage in its industry [1] - The company benefits from network effects that drive exponential growth and has achieved market penetration in high-growth sectors [1] Financial Health & Risk Management - The company shows sustainable revenue growth with efficient cash flow and maintains a strong balance sheet [1] - Hims & Hers avoids excessive dilution and financial weakness, ensuring a long-term survival runway [1] Valuation & Asymmetric Risk/Reward - The valuation approach includes revenue multiples compared to peers and DCF modeling, with a focus on institutional backing and market sentiment analysis [1] - The company ensures downside protection while offering significant upside potential [1] Portfolio Construction & Risk Control - The investment strategy includes core positions (50-70%) in high-confidence, stable plays, growth bets (20-40%) in high-risk, high-reward opportunities, and speculative investments (5-10%) in moonshot disruptors [1]

Core Insights - Hims & Hers Health, Inc. (HIMS) has seen a significant stock increase of 85.1% over the past three months, outperforming the industry and major competitors [1][10] - The company has made strategic moves, including the acquisition of ZAVA, a digital health platform in Europe, and a collaboration with Novo Nordisk [2][12][14] - Despite challenges such as lower wholesale revenues and contracting gross margins, HIMS is expected to maintain positive market momentum [3][8][17] Financial Performance - HIMS anticipates second-quarter 2025 revenues between $530 million and $550 million, reflecting a year-over-year increase of 68-74%, and full-year revenues between $2.3 billion and $2.4 billion, representing growth of 56-63% from 2024 [9][10] - The Zacks Consensus Estimate for second-quarter revenues is $551.8 million, with earnings per share estimated at 17 cents [9] - HIMS' forward 12-month price-to-sales (P/S) ratio is 5.3X, lower than the industry average of 6X but higher than its five-year median of 2.6X [18] Strategic Developments - The acquisition of ZAVA is a key step in HIMS' international expansion, targeting markets in the U.K., Germany, France, and Ireland [14][15] - HIMS plans to enhance its digital health offerings in Europe, focusing on personalized care across various health domains [15] - The company has also announced a $870 million convertible senior notes offering to support global expansion and investment in AI and personalized treatments [13] Market Position - HIMS has outperformed competitors like Teladoc Health, Inc. and American Well Corporation, whose shares have declined by 13.7% and 13.3%, respectively, in the same timeframe [7] - The company is positioned favorably in terms of core business strength and global opportunities, with a Zacks Rank of 2 (Buy) indicating strong growth prospects [22][23]

I am a full-time analyst interested in a wide range of stocks. With my unique insights and knowledge, I hope to provide other investors with a contrasting view of my portfolio, given my particular background.If you have any questions, feel free to reach out to me via a direct message on Seeking Alpha or leave a comment on one of my articles.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the ...